Health Care

Formycon AG partners with OneSource Specialty Pharma for exclusive biopharma manufacturing, boosting speed‑to‑market and investor confidence in the competitive biosimilar arena.

New at‑home LEQEMBI® subcutaneous autoinjector cleared by the FDA, matching IV efficacy and opening early‑stage Alzheimer’s treatment to patients worldwide.

Humanwell’s FDA‑approved Nidanib Soft Gel Capsules open U.S. market doors, boosting growth, safety and global reach in pharma.

Explore Axsome Therapeutics’ rise to $233.8 Nasdaq, its focus on pain & neurological drugs, and why its growth fuels biopharma innovation.

Explore Zentek Ltd.’s pioneering graphene composites—merging health care and construction tech—while weighing its TSX stock’s growth potential and R&D focus.

Discover how Calgary‑based VentriPoint Diagnostics is revolutionizing heart disease detection with 3‑D imaging tech and AI‑powered models—boosting accuracy and early care.

Intuitive Surgical’s earnings reveal the future of surgical tech: market‑cap $144B, 49.44 P/E, and analyst‑surprise potential amid economic uncertainty.

New CMO Dr. Dominic Borie joins Cue Biopharma to accelerate oncology biologics and boost investor confidence amid volatile valuation.

BioCryst Pharmaceuticals pioneers oral, small‑molecule drugs for rare enzyme‑related diseases, driving global innovation and patient access in biotech.

Merck’s FDA approval of KEYTRUDA + Padcev combo offers new hope for muscle‑invasive bladder cancer patients, boosting treatment options and investor outlook.